(DRAFT) AGENDA

BLOOD PRODUCTS ADVISORY COMMITTEE 86th Meeting - March 9-10, 2005 Hilton Hotel, Washington DC North / Gaithersburg 620 Perry Parkway, Gaithersburg, MD 20877

Thursday, March 9, 2006

- 8:00 a.m. Welcome, Statement of Conflict of Interest, Acknowledgement of New Members, Announcements
- 8:15 a.m. Committee Updates
 - Meeting Summary of DHHS Advisory Committee on Blood Safety and Availability Jerry Holmberg, PhD, Executive Secretary, Advisory Committee on Blood Safety and Availability (15')
 - Current Considerations for blood donor screening for West Nile Virus -Pradip Akolkar, Ph.D., OBRR, FDA (15')
 - Classification of Transfusion Recipient ID Systems Sheryl Kochman, OBRR, FDA (15')
 - Workshop Summary Behavior- Based Donor Deferrals in the NAT ERA- Andrew Dayton, MD, OBRR, FDA (15')

9:15 a.m.

- I. Rapid Tests for Detection of Bacterial Contamination of Platelets
 - A. Introduction and Background Jaroslav Vostal, MD, PhD, OBRR, FDA (30')
- 9:45 a.m. OPEN PUBLIC HEARING
- 10:30 a.m. BREAK
- 11:00 a.m. OPEN PUBLIC HEARING
- 11:30 a.m. Open Committee Discussion
 - B. FDA Perspective and Questions for the Committee
 - C. Committee Discussion and Recommendations
- 12:30 p.m. LUNCH

BLOOD PRODUCTS ADVISORY COMMITTEE

Thursday, March 9, 2005

- 1:30 p.m.
 - II. Public Comments on "Guidance for Industry and FDA Review Staff: Collection of Platelets by Automated Methods (DRAFT)"
 - A. Introduction and Review of Comments- Alan Williams, PhD, Director, Division of Blood Applications, OBRR, FDA (30')
 - B. Industry presentation TBD (30')
- 2:30 p.m. OPEN PUBLIC HEARING
- 3:30 p.m. BREAK
- 4:00 p.m. Open Committee Discussion
 - C. FDA Perspective and Questions for the Committee
 - D. Committee Discussion and Recommendations
- 5:00 p.m. Adjournment

Friday, March 10, 2005

- 8:30 a.m.
 - III. Proposed Studies to Support the Approval of Over-the-Counter (OTC) Home-Use HIV Test Kits
 - A. Background and Proposed Studies Elliot Cowan, PhD, OBRR, FDA (40')
 - B. Clinical Experience with Approved Rapid HIV Tests Bernard Branson, M.D., CDC (20')
- 9:30 a.m. OPEN PUBLIC HEARING
- 10:30 a.m. Break
- 11:00 a.m. Open Committee Discussion
 - C. Questions for the Committee
 - D. Committee Discussion and Recommendations
- 12:00 p.m. LUNCH

BLOOD PRODUCTS ADVISORY COMMITTEE

- 1:00 p.m.
 - IV. Summary of the Office of Blood Research and Review Site Visit (July 22, 2005)
 - A. CBER Research Overview- Kathryn M. Carbone, M.D., ADR, IOD, CBER (10')
 - B. OBRR Research Overview- Jay Epstein, M.D., Director, OBRR
 (15')
 - C. Questions- 20'

1:45 p.m.

- V. Review of Research Program Site Visit of the Division of Hematology Laboratories, OBRR, CBER (Oct 6, 2005)
 - A. Overview of the Division of Hematology Research program Basil Golding, M.D., Director, DH, OBRR- 5'
 - 1. Laboratory of Biochemistry and Vascular Biology

Abdu Alayash, Ph.D. - 10'

Felice D'Agnillo, Ph.D. - 5'

Ouestions-15'

2. Laboratory of Cellular Hematology

Jaroslav Vostal, M.D. Ph.D. - 5'

Jan Simak, Ph.D. - 5'

Ouestions-15'

- 2:45 p.m. Open Public Hearing
- 2:55 p.m. Break and Clear the Room
- 3:15 p.m. Closed Session Discussion of the OBRR Office Site Visit Review Report and the Division of Hematology laboratory site visit report
- 4:15 p.m. Adjournment